ZEVALIN® (ibritumomab tiuxetan) injection for intravenous use is a prescription medication that has three parts: two infusions of rituximab and one injection of Yttrium-90 (Y-90) ZEVALIN. Rituximab is used to reduce the number of B-cells in your blood and Y-90 ZEVALIN is given to treat your non-Hodgkin’s lymphoma (NHL).
The ZEVALIN therapeutic regimen is used to treat adult patients with:
Relapsed or refractory, low-grade or follicular B-cell non-Hodgkin’s lymphoma (NHL)
Previously untreated follicular NHL who achieve a partial or complete response to first-line chemotherapy
Zevalin is an immunoconjugate between the monoclonal antibody ibritumomab and the linker-chelator tiuxetan arising from the stable thiourea covalent link. This linker-chelator offers an Indium-111 or Yttrium-90.0 site for high affinity, conformationally limited chelation. Ibritumomab tiuxetan has an average molecular mass of 148 kDa. Ibritumomab, a murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, is the antibody moiety of zevalin. Ibritumomab tiuxetan is a transparent, colorless, sterile, preservative-free, pyrogen-free solution containing fine particles. It is provided in single-use vials containing 3.2 mg of ibritumomab in 2 mL of 0.9% sodium chloride. Zevalin is a protein used in conjunction with other drugs to treat non-Hodgkin lymphoma that attacks white blood cells. Zevalin injection for intravenous use is a prescription medication that has three parts: two infusions of rituximab and one injection of Yttrium-90 Zevalin. Rituximab is used to reduce the number of B-cells in your blood and Y-90 Zevalin is given to treat your non-Hodgkin’s lymphoma (NHL). The Zevalin therapeutic regimen is used to treat patients with: Low-grade or follicular B-cell NHL that has relapsed during or after treatment with other anticancer drugs; newly diagnosed follicular NHL following a response to initial anticancer therapy.